Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

About 700 antibody-secreting hybrids were obtained by fusion of lymphocytes, (harvested from mice hyperimmunized with the human gastric carcinoma line KATO III) and P3-X63-Ag8-653 myeloma cells. Antibody specificity was screened in ELISA performed on glutaraldehyde-fixed cultured cells and on paraffin-embedded tissue sections stained with the method of avidin-biotin-peroxidase. When tested in ELISA, the monoclonal antibody produced by the hybrid clone BD-5 was found to bind only to the cell line used as immunogen, among the many neoplastic or normal human cell lines tested. When assayed on paraffin sections with the avidin-biotin-peroxidase method, the BD-5 monoclonal antibody stained gastric carcinomas, but not the normal mucosa. Pancreatic carcinomas were also stained, while the corresponding normal gland was not. The antibody strongly stained the normal colonic and small intestinal mucosa. Among the other normal or neoplastic tissues tested, a weak reactivity was observed only with some epithelial cells of the salivary glands and with some carcinoma cells of the uterus and of the lung. It is concluded that the BD-5 antibody reacts with an epitope normally present on intestinal mucosa, which, following neoplastic transformation, is ectopically expressed also on gastric and pancreatic carcinomas. This monoclonal could represent a useful reagent for histopathological diagnosis.
 ...
PMID:Production of monoclonal antibodies for the immunohistochemical detection of gastric carcinomas. 355 23

Immunization of B10.D2 Ign mice against a (BALB/c X NZB)F1 murine B lymphoma cell line (WEHI-5) and subsequent fusion of immune spleen cells with a drug sensitive myeloma (P3 X 63-Ag8) has resulted in the generation of a series of hybridoma cell lines. One of these clones, BD5-334.5, secretes an antibody which reacts with a determinant, designated Lym 7.2, which demonstrates an identical tissue and strain distribution as the conventionally defined Ly 7.2 antigen. Furthermore, anti-Ly 7.2 alloantiserum significantly blocks reaction of the anti-Lym 7.2 monoclonal antibody with BALB/c splenocytes. Lym 7.2 is present on a majority of splenocytes, peripheral blood leukocytes, and lymph node cells. However, B cells express considerably higher cell surface density of this antigen than peripheral T lymphocytes. This antigen was not detected on erythrocytes, kidney, liver, or brain. Moreover, Lym 7.2 is present on approximately 15% of normal thymocytes, and 15% of bone marrow cells, and is expressed on cortisone resistant thymocytes. Quantitative flow cytometry analysis demonstrated that the antigen is present at approximately half the cell surface density on spleen cells from F1 mice between Lym 7.2 positive and Lym 7.2 negative mice, but on the same percentage of cells as Lym 7.2 positive inbred strains. Data from backcross analysis suggest that a single locus is encoding this antigen. Mitogen blasts, induced with PHA, ConA, and LPS, all express the Lym 7.2 marker.
 ...
PMID:Lym 7.2: monoclonal antibody defining an alloantigen similar or identical to Ly 7.2. 620 26